CCND3 and neoplasm: Moreover, rapamycin has been tested alone or in combination with Janus kinase (JAK), ABL protein inhibitors (Tasian et al., 2017), focal adhesion kinase (FAK) or also with cyclin D3 (CCND3) and CDK4/6 inhibitors (Li et al., 2015; Pikman et al., 2017) in xenografts mouse model and cancer cell lines, exhibiting synergistic effects on anti-tumor.